Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination

Clinical trial NCT03462212 · UNKNOWN

Trial details

NCT number: NCT03462212
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Start date: 2021-03-17
Primary completion: 2025-03-01
Enrollment: 290

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.